TNF and inflammatory bowel disease: By implementing such strategies, we can better leverage the benefits of biosimilar anti-TNF-α medicines and better support the ‘top-down’ approach to IBD treatment, ultimately improving long-term disease management and patient outcomes, as well as paving the way for the future biosimilar landscape in IBD.